upsid set stage strong
convinc result organ sale growth
expect go tmo print subdu given weak peer
pre-announce sofer macro environ tmo result solidli put
doubt bed total revenu y/i flat fx ahead
estimate organ growth vs estimate
led stellar key lss segment margin broadli
in-lin expect adj ep came ahead benefit
debt refinanc first look detail
market stabl hole poke strong run continu
main driver beat life scienc solut segment strong biopharma
spend bioprocess mirror comment merck kgaa recent
bu trip also saw broad-bas strength sdx specialti diagnost
lp lab product servic area nitpick ai analyt instrument
surpris given consist management commentari choppi
industri market stack tough comp particularli fei geographi china
expect finish mid-teen europ acceler
sequenti high-singl digit allevi concern two biggest
pressur area tool rais fy guid see organ adj ep
rais larg captur beat non-op item reflect
consid prudent conservat expect
model tweak remain focu stock year-end
estim sale y/i organ fx
 adj ep y/i sale
organ adj ep yoy reiter buy
rate rais po dcf base wacc termin
growth rate last major catalyst prior year-end pass think
resum role safeti given uncertainti elsewher market
continu outperform setup look increasingli favor
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
thermo fisher scientif largest
consist analyt instrument lab
equip consum softwar servic
use throughout research drug manufactur
diagnost food consum product safeti
environment test
thermo fisher scientif largest life scienc
tool compani think recent acquisit
complementari technolog higher growth
on-going process improv initi
expand footprint emerg appli
market help grow revenu steadili
line even modestli better
overal tool market deliv low teen ep
compound-annual-growth-rate next sever year
po base dcf model assum wacc previous
termin growth rate impli multipl approxim
ep estim roughli line compani histor averag given size
market leadership matur stabil compani consum focus
busi believ dcf appropri way valu compani risk
price object deal integr risk lower-than-expect deal synergi
slower growth emerg market price eros lower healthcar util trend
soft uptak new product competit weak fund
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
